Plain-English translation of NCT02965326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic Fibrosis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Doctors want to find a better way to predict whether cystic fibrosis medications will work well for each patient before they've been taking them for months. This study tests whether cells taken from your nose or rectum can show in a lab whether Ivacaftor or Lumacaftor/Ivacaftor will be effective for you. If successful, this could help doctors choose the best treatment faster.
Right now, doctors have to wait 6–12 months to see if a medication is actually helping a patient with cystic fibrosis. This study aims to develop a faster way to predict treatment success using lab tests, so patients and doctors can make better decisions sooner.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital for tissue collection: a small sample will be taken from your nose or rectum (or both). These cells will be grown in the lab and tested with your current or planned medication to see how well they respond. You'll also have standard cystic fibrosis check-ups at 6 and 12 months so doctors can compare your lab results with how you're actually doing clinically.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France
Sponsor
Hôpital Necker-Enfants Malades
Collaborators
Association Mucoviscidose-ABCF2, Vaincre la Mucoviscidose
Enrollment target
~75 participants
Started
May 2016
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Isabelle Sermet, MD, PhD
APHP
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.